Current and future therapeutic options for the management of gout

American Journal of Therapeutics

Volumn 17, Issue 4, 2010, Pages 402-417

  Whelton, Andrew ^a,b,c  

^a Universal Clinical Research Center Inc   (United States)

^b ScienceFirst LLC   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

febuxostat; gout; hyperuricemia; uricase

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; BENZBROMARONE; COLCHICINE; COLCRYS; CORTICOSTEROID; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; MORIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PEGLOTICASE; PLACEBO; PROBENECID; RASBURICASE; RDEA 594; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ULORIC; UNCLASSIFIED DRUG; URATE OXIDASE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; ANAPHYLAXIS; ANXIETY; ARTHROPATHY; BREATHING DISORDER; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRESS SYNDROME; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DYSPNEA; ENZYME REPLACEMENT; ESSENTIAL HYPERTENSION; GOUT; HEMOLYSIS; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LOW BACK PAIN; LOW DRUG DOSE; LOW FAT DIET; METABOLIC SYNDROME X; METHEMOGLOBINEMIA; MUSCLE SPASM; MUSCLE STIFFNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NECK PAIN; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PURINE METABOLISM; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URTICARIA; VOMITING; ANIMAL; COMPLICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; METABOLISM;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GOUT; HUMANS; HYPERURICEMIA; QUALITY OF LIFE; URIC ACID; URICOSURIC AGENTS;

EID: 77955012787     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181df8ad2     Document Type: Review

References (144)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26-35.
2. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29: 2403-2406.
3. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-1587.
4. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321-325.
5. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol. 2008;20: 167-172.
6. Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008;58:2587-2590.
7. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48:582-586.
8. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(Suppl 1):S1.
9. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52:283-289.
10. Choi JW, Ford ES, Gao X, et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59:109-116.
11. Emmerson BT. Effect of oral fructose on urate production. Ann Rheum Dis. 1974;33:276-280.
12. Gao X, Qi L, Qiao N, et al. Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. Hypertension. 2007;50:306-312.
13. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci. 2007;4:83-93.
14. Oda M, Satta Y, Takenaka O, et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19:640-653.
15. Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout: new insights into pathogenesis and treatment. Bull NYU Hosp Jt Dis. 2007;65:215-221.
16. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2004;51: 1023-1029.
17. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277-1281.
18. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-426.
19. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27:1501-1505.
20. Kippen I, Klinenberg JR, Weinberger A, et al. Factors affecting urate solubility in vitro. Ann Rheum Dis. 1974; 33:313-317.
21. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301-1311.
22. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004;64:2399-2416.
23. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-554.
24. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007;57:1324-1328.
25. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal antiinflammatory drugs. Br J Clin Pharmacol. 1987;24:33-36.
26. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36:1041-1048.
27. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8(Suppl 1):S3.
28. Martinon F, Glimcher LH. Gout: new insights into an old disease. J Clin Invest. 2006;116:2073-2075.
29. Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 2007;56:3183-3188.
30. Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003;64: 1022-1026.
31. Kramer HM and Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37-42.
32. Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, et al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheumatol. 2005;32:2189-2191.
33. Tarng DC, Lin HY, Shyong ML, et al. Renal function in gout patients. Am J Nephrol. 1995;15:31-37.
34. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005;16:791-799.
35. Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407-2413.
36. Su BY, Lai HM, Chen CJ, et al. Ischemia heart disease and greater waist circumference are risk factors of renal function deterioration in male gout patients. Clin Rheumatol. 2008;27:581-586.
37. Borges RL, Hirota AH, Quinto BM, et al. Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. J Clin Hypertens (Greenwich). 2009;11:253-259.
38. Eraranta A, Kurra V, Tahvanainen AM, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens. 2008;26: 1661-1668.
39. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991-F997.
40. Sanchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008;23:1179-1185.
41. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystalindependent mechanism. Hypertension. 2001;38:1101-1106.
42. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67:237-247.
43. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-2897.
44. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283:F1105-F1110.
45. Johnson RJ, Feig DI, Herrera-Acosta J, et al. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005;45:18-20.
46. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48:1031-1036.
47. Jones DP, Richey PA, Alpert BS, et al. Serum uric acid and ambulatory blood pressure in children with primary hypertension. Pediatr Res. 2008;64:556-561.
48. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247-252.
49. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006;48:1037-1042.
50. Sundstrom J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28-33.
51. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49: 298-303.
52. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120: 442-447.
53. Sui X, Church TS, Meriwether RA, et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57:845-852.
54. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57:109-115.
55. Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31:361-362.
56. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168:1104-1110.
57. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47:1567-1570.
58. Colvine K, Kerr AJ, McLachlan A, et al. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support. N Z Med J. 2008;121:73-81.
59. Choi HK and Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900.
60. Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49:141-146.
61. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885-892.
62. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-1324.
63. Colcrys- Prescribing Information. Philadelphia, PA: AR Scientific Inc; 2009.
64. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallelgroup, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-1068.
65. US Department of Health and Human Services. Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys). Vol.2010. Silver Spring, MD: US Food and Drug Administration, 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/ Postmarket DrugSafetyInformationforPatientsandPro viders/ DrugSafetyInformationforHeathcareProfessionals/ ucm174315.htm. Accessed on January 15, 2010.
66. Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 2006;116:2262-2271.
67. Torres R, Macdonald L, Croll SD, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis. 2009;68: 1602-1608.
68. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613-1617.
69. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28.
70. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28: 577-580.
71. Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12:61-65.
72. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol. 1998;431:13-18.
73. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of uratelowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-360.
74. Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010; 22:165-172.
75. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46:1372-1374.
76. Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165:742-748.
77. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29:1350-1355.
78. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66:1056-1058.
79. Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30:495-503.
80. Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27:585-591.
81. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31: 2429-2432.
82. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353: 2450-2461.
83. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-1548.
84. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat for the treatment of hyperuricemia and gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.
85. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925-934.
86. Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26:445-449.
87. Terkeltaub R. Gout in 2006: the perfect storm. Bull NYU Hosp Jt Dis. 2006;64:82-86.
88. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
89. Allopurinol U.S.Prescribing Information. Weston, FL: Apotex Corp.; 2006.
90. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646-1650.
91. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:51-56.
92. Probenecid U.S. Prescribing Information. Corona, CA: Watson Laboratories Inc; 2003.
93. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57:545-549.
94. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 1999;5:49-55.
95. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51-56.
96. Chohan S, Becker MA. Update on emerging uratelowering therapies. Curr Opin Rheumatol. 2009;21:143-149.
97. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17:397-414.
98. Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62:572-575.
99. Uloric- Full Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals North America, Inc.; 2009.
100. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005;76: 1835-1847.
101. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273-1278.
102. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48: 188-194.
103. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004;23:1111-1116.
104. Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 2004;23:1117-1118.
105. Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12:22-34.
106. Whelton A, Becker MA, MacDonald P, et al. Gout subjects with hyperuricemia and renal impairment treated with febuxostat or allopurinol for 6 months. J Am Soc Nephrol. 2009;20:669A. Abstract F-P01115.
107. Elitek (rasburicase) Prescribing Information. Bridgewater, NJ: Sanofi-aventis; 2009.
108. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy- associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19:34-38.
109. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.
110. Malaguarnera M, Vacante M, Russo C, et al. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother. 2009;10: 737-742.
111. De Angelis S, Noce A, Di Renzo L, et al. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blindrandomized study. Eur Rev Med Pharmacol Sci. 2007;11: 179-184.
112. Richette P, Briere C, Hoenen-Clavert V, et al. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34:2093-2098.
113. Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8:R12.
114. Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56:1021-1028.
115. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum. 2008;58: 2882-2891.
116. Baraf HS, Matsumoto AK, Maroli AN, et al. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum. 2008;58:3632-3634.
117. FDA Arthritis Advisory Committee Briefing Document for Krystexxa (Pegloticase). Overview of the June 16, 2009 AAC Meeting to Discuss BLA 125293 for pegloticase (Krystexxa) for the treatment of refractory gout. Department of Health & Human Services. Food & Drug Administration Center for Drug Evaluation & Research, Division of Anesthesia, Analgesia and Rheumatology Products; 2009.
118. FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout: Savient Pharmaceuticals, Inc. PR Newswire; 2009. Available at: http://investor.savient. com/releasedetail.cfm?ReleaseID=390150. Accessed January 15, 2010.
119. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM): Savient Pharmeceuticals, Inc. PR Newswire; 2009. Available at: http://investor.savient. com/releasedetail.cfm? ReleaseID=400470. Accessed January 15, 2010.
120. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy: Savient Pharmaceuticals, Inc. Savient Pharmaceutical, Inc. PR Newswire; 2010. Available at: http://investor. savient.com/releasedetail. cfm?ReleaseID=451833. Accessed March 22, 2010.
121. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002; 417:447-452.
122. Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum. 2006;54:292-300.
123. Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006;17:1791-1795.
124. Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem. 2008;283:26834-26838.
125. Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5:e197.
126. Augustin R, Carayannopoulos MO, Dowd LO, et al. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem. 2004;279:16229-16236.
127. Dalbeth N and Merriman T. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. Rheumatology (Oxford). 2009;48:222-226.
128. Doring A, Gieger C, Mehta D, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet. 2008;40:430-436.
129. Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372: 1953-1961.
130. Van Aubel RA, Smeets PH, van den Heuvel JJ, et al. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol. 2005;288:F327-F333.
131. Ardea Biosciences, Inc. Company Update. January 11, 2010. Available at: http://www.ardeabio.com/Docs/Company% 20Update%201-7-10-FINAL3.pdf. Accessed January 15, 2010.
132. Yu Z, Fong WP, Cheng CH. The dual actions of morin (3,5,7,2',4'- pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity. J Pharmacol Exp Ther. 2006;316:169-175.
133. Yu Z, Fong WP, Cheng CH. Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. Drug Metab Dispos. 2007;35:981-986.
134. Zhao X, Zhu JX, Mo SF, et al. Effects of cassia oil on serum and hepatic uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. J Ethnopharmacol. 2006;103:357-365.
135. Zhu JX,Wang Y, Kong LD, et al. Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. J Ethnopharmacol. 2004;93:133-140.
136. Wang X, Wang CP, Hu QH, et al. The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. J Ethnopharmacol. 2010;128:107-115.
137. Kong LD, Cheng CH, Tan RX. Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones. J Ethnopharmacol. 2004;91: 351-355.
138. Yan H, Ma Y, Liu M, et al. The dual actions of Paederia scandens extract as a hypouricemic agent: xanthine oxidase inhibitory activity and uricosuric effect. Planta Med. 2008;74:1345-1350.
139. Gibson T, Rodgers V, Potter C, et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis. 1982;41:59-65.
140. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39: 1227-1233.
141. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-59.
142. Perez-Ruiz F, Calabozo M, Herrero-Beites AM, et al. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron. 2000;86:287-291.
143. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27:435-440.
144. Whelton A, Macdonald P, Lloyd E, et al. Beneficial relationship of serum urate reduction and estimated glomerular filtration rate improvement/maintenance in hyperuricemic gout subjects treated for up to 5.5 years with febuxostat. Poster presented at: American College of Rheumatology Annual Meeting; October 24-29, 2008; San Francisco, CA. Available at: http://acr.confex. com/acr/2008/webprogram/Paper2796.html. Accessed January 15, 2010.